Poor to modest agreement between rheumatoid arthritis response measures in clinical practice

Kaleb Michaud, T. R. Mikuls, S. E. Call, A. M. Reimold, R. Hooker, G. S. Kerr, J. S. Richards, L. Caplan, G. W. Cannon

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: To evaluate the agreement among several rheumatoid arthritis (RA) response measures in a clinical setting. Methods: 529 patients with RA were seen at 2 regular visits where the following response measures were determined: ACR-20, EULAR good or moderate (EULAR-GM), Simplified Disease Activity index moderate (SDAI-M), Clinical DAI moderate (CDAI-M), and Patient Reported Outcomes Index-M 20 (PRO-IM-20). Each measure was modified to include a "worse" response, i.e. the inverse of the respective guidelines for a positive improvement response. Introduced for comparison was the Real-time Assessment of Disease Activity in Rheumatoid Arthritis (RADARA), a response measure that registers improvement if the patient's tender and swollen joint counts and HAQ score all improve and worsening if all three increase. Contingency tables comparing the three responses (worse, no change, and improvement) along with Cohen's kappa were calculated. Results: The mean (SD) baseline characteristics of the patients included: age 66.5 (10.7) years, RA duration 12.9 (11.0) years, 91.3% male, 84.1% rheumatoid factor positive, and a Disease Activity Score-28 of 3.5 (1.3). The percentage of patients who improved/worsened were as follows: ACR-20 4.7/9.1, EULAR-GM 23.4/26.3, SDAI-M 16.1/20.6, CDAI-M 16.3/20.0, PRO-IM-20 22.5/34.4, and RADARA 7.0/11.5. Agreement (kappa) was poor to slight (≤ 0.4) between most of the response measures with the exception of RADARA/ACR-20 which showed substantial agreement (0.67) and SDAI/EULAR-GM and CDAI/EULAR-GM, which showed moderate agreement (0.54 and 0.52, respectively). Conclusion: RA response measures can be made more informative by the addition of a "worse" response, although even in this case the agreement in the clinic setting is primarily poor to moderate.

Original languageEnglish (US)
Pages (from-to)633-640
Number of pages8
JournalClinical and Experimental Rheumatology
Volume27
Issue number4
StatePublished - Jul 2009

Fingerprint

Rheumatoid Arthritis
ametantrone
Rheumatoid Factor
Joints
Guidelines

Keywords

  • ACR improvement criteria
  • Disease activity
  • Disease activity score
  • Outcome assessment
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Michaud, K., Mikuls, T. R., Call, S. E., Reimold, A. M., Hooker, R., Kerr, G. S., ... Cannon, G. W. (2009). Poor to modest agreement between rheumatoid arthritis response measures in clinical practice. Clinical and Experimental Rheumatology, 27(4), 633-640.

Poor to modest agreement between rheumatoid arthritis response measures in clinical practice. / Michaud, Kaleb; Mikuls, T. R.; Call, S. E.; Reimold, A. M.; Hooker, R.; Kerr, G. S.; Richards, J. S.; Caplan, L.; Cannon, G. W.

In: Clinical and Experimental Rheumatology, Vol. 27, No. 4, 07.2009, p. 633-640.

Research output: Contribution to journalArticle

Michaud, K, Mikuls, TR, Call, SE, Reimold, AM, Hooker, R, Kerr, GS, Richards, JS, Caplan, L & Cannon, GW 2009, 'Poor to modest agreement between rheumatoid arthritis response measures in clinical practice', Clinical and Experimental Rheumatology, vol. 27, no. 4, pp. 633-640.
Michaud, Kaleb ; Mikuls, T. R. ; Call, S. E. ; Reimold, A. M. ; Hooker, R. ; Kerr, G. S. ; Richards, J. S. ; Caplan, L. ; Cannon, G. W. / Poor to modest agreement between rheumatoid arthritis response measures in clinical practice. In: Clinical and Experimental Rheumatology. 2009 ; Vol. 27, No. 4. pp. 633-640.
@article{392b3f448f6d4963bdc44ce41bd09ce4,
title = "Poor to modest agreement between rheumatoid arthritis response measures in clinical practice",
abstract = "Objective: To evaluate the agreement among several rheumatoid arthritis (RA) response measures in a clinical setting. Methods: 529 patients with RA were seen at 2 regular visits where the following response measures were determined: ACR-20, EULAR good or moderate (EULAR-GM), Simplified Disease Activity index moderate (SDAI-M), Clinical DAI moderate (CDAI-M), and Patient Reported Outcomes Index-M 20 (PRO-IM-20). Each measure was modified to include a {"}worse{"} response, i.e. the inverse of the respective guidelines for a positive improvement response. Introduced for comparison was the Real-time Assessment of Disease Activity in Rheumatoid Arthritis (RADARA), a response measure that registers improvement if the patient's tender and swollen joint counts and HAQ score all improve and worsening if all three increase. Contingency tables comparing the three responses (worse, no change, and improvement) along with Cohen's kappa were calculated. Results: The mean (SD) baseline characteristics of the patients included: age 66.5 (10.7) years, RA duration 12.9 (11.0) years, 91.3{\%} male, 84.1{\%} rheumatoid factor positive, and a Disease Activity Score-28 of 3.5 (1.3). The percentage of patients who improved/worsened were as follows: ACR-20 4.7/9.1, EULAR-GM 23.4/26.3, SDAI-M 16.1/20.6, CDAI-M 16.3/20.0, PRO-IM-20 22.5/34.4, and RADARA 7.0/11.5. Agreement (kappa) was poor to slight (≤ 0.4) between most of the response measures with the exception of RADARA/ACR-20 which showed substantial agreement (0.67) and SDAI/EULAR-GM and CDAI/EULAR-GM, which showed moderate agreement (0.54 and 0.52, respectively). Conclusion: RA response measures can be made more informative by the addition of a {"}worse{"} response, although even in this case the agreement in the clinic setting is primarily poor to moderate.",
keywords = "ACR improvement criteria, Disease activity, Disease activity score, Outcome assessment, Rheumatoid arthritis",
author = "Kaleb Michaud and Mikuls, {T. R.} and Call, {S. E.} and Reimold, {A. M.} and R. Hooker and Kerr, {G. S.} and Richards, {J. S.} and L. Caplan and Cannon, {G. W.}",
year = "2009",
month = "7",
language = "English (US)",
volume = "27",
pages = "633--640",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "4",

}

TY - JOUR

T1 - Poor to modest agreement between rheumatoid arthritis response measures in clinical practice

AU - Michaud, Kaleb

AU - Mikuls, T. R.

AU - Call, S. E.

AU - Reimold, A. M.

AU - Hooker, R.

AU - Kerr, G. S.

AU - Richards, J. S.

AU - Caplan, L.

AU - Cannon, G. W.

PY - 2009/7

Y1 - 2009/7

N2 - Objective: To evaluate the agreement among several rheumatoid arthritis (RA) response measures in a clinical setting. Methods: 529 patients with RA were seen at 2 regular visits where the following response measures were determined: ACR-20, EULAR good or moderate (EULAR-GM), Simplified Disease Activity index moderate (SDAI-M), Clinical DAI moderate (CDAI-M), and Patient Reported Outcomes Index-M 20 (PRO-IM-20). Each measure was modified to include a "worse" response, i.e. the inverse of the respective guidelines for a positive improvement response. Introduced for comparison was the Real-time Assessment of Disease Activity in Rheumatoid Arthritis (RADARA), a response measure that registers improvement if the patient's tender and swollen joint counts and HAQ score all improve and worsening if all three increase. Contingency tables comparing the three responses (worse, no change, and improvement) along with Cohen's kappa were calculated. Results: The mean (SD) baseline characteristics of the patients included: age 66.5 (10.7) years, RA duration 12.9 (11.0) years, 91.3% male, 84.1% rheumatoid factor positive, and a Disease Activity Score-28 of 3.5 (1.3). The percentage of patients who improved/worsened were as follows: ACR-20 4.7/9.1, EULAR-GM 23.4/26.3, SDAI-M 16.1/20.6, CDAI-M 16.3/20.0, PRO-IM-20 22.5/34.4, and RADARA 7.0/11.5. Agreement (kappa) was poor to slight (≤ 0.4) between most of the response measures with the exception of RADARA/ACR-20 which showed substantial agreement (0.67) and SDAI/EULAR-GM and CDAI/EULAR-GM, which showed moderate agreement (0.54 and 0.52, respectively). Conclusion: RA response measures can be made more informative by the addition of a "worse" response, although even in this case the agreement in the clinic setting is primarily poor to moderate.

AB - Objective: To evaluate the agreement among several rheumatoid arthritis (RA) response measures in a clinical setting. Methods: 529 patients with RA were seen at 2 regular visits where the following response measures were determined: ACR-20, EULAR good or moderate (EULAR-GM), Simplified Disease Activity index moderate (SDAI-M), Clinical DAI moderate (CDAI-M), and Patient Reported Outcomes Index-M 20 (PRO-IM-20). Each measure was modified to include a "worse" response, i.e. the inverse of the respective guidelines for a positive improvement response. Introduced for comparison was the Real-time Assessment of Disease Activity in Rheumatoid Arthritis (RADARA), a response measure that registers improvement if the patient's tender and swollen joint counts and HAQ score all improve and worsening if all three increase. Contingency tables comparing the three responses (worse, no change, and improvement) along with Cohen's kappa were calculated. Results: The mean (SD) baseline characteristics of the patients included: age 66.5 (10.7) years, RA duration 12.9 (11.0) years, 91.3% male, 84.1% rheumatoid factor positive, and a Disease Activity Score-28 of 3.5 (1.3). The percentage of patients who improved/worsened were as follows: ACR-20 4.7/9.1, EULAR-GM 23.4/26.3, SDAI-M 16.1/20.6, CDAI-M 16.3/20.0, PRO-IM-20 22.5/34.4, and RADARA 7.0/11.5. Agreement (kappa) was poor to slight (≤ 0.4) between most of the response measures with the exception of RADARA/ACR-20 which showed substantial agreement (0.67) and SDAI/EULAR-GM and CDAI/EULAR-GM, which showed moderate agreement (0.54 and 0.52, respectively). Conclusion: RA response measures can be made more informative by the addition of a "worse" response, although even in this case the agreement in the clinic setting is primarily poor to moderate.

KW - ACR improvement criteria

KW - Disease activity

KW - Disease activity score

KW - Outcome assessment

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=70350163827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350163827&partnerID=8YFLogxK

M3 - Article

C2 - 19772796

AN - SCOPUS:70350163827

VL - 27

SP - 633

EP - 640

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 4

ER -